3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
7
Phase 3
4
Phase 1/2
3
Phase NA
1
Phase 4
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
657
Carcinoma, Renal Cell
385
Carcinoma, Non-Small-Cell Lung
243
Urinary Bladder Neoplasms
235
Breast Neoplasms
221
Melanoma
193
Ovarian Neoplasms
192
Neoplasms
178
Colorectal Neoplasms
161
Kidney Neoplasms
152
Neoplasm Metastasis
131
Carcinoma, Transitional Cell
127
Pancreatic Neoplasms
124
Lung Neoplasms
121
Stomach Neoplasms
114
Squamous Cell Carcinoma of Head and Neck
107
Sarcoma
99
Head and Neck Neoplasms
89
Uterine Cervical Neoplasms
88
Carcinoma, Hepatocellular
80
Triple Negative Breast Neoplasms
76
Esophageal Neoplasms
76
Endometrial Neoplasms
75
Colonic Neoplasms
64
Wilms Tumor
56
Small Cell Lung Carcinoma
55
Carcinoma, Ovarian Epithelial
48
Neuroblastoma
47
Liver Neoplasms
46
Testicular Neoplasms
45
Interventions
darolutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Male Urogenital Diseases
×
Genitourinary
×
Clear all
NCT07103018
2026-03-23
STRIKE-001
K36 Therapeutics, Inc.
Phase 1
Recruiting
144 enrolled